Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Promising efficacy of BI-1206, an antibody targeting FcγRIIB in combination with rituximab and acalabrutinib in R/R NHL patients NHL

View Full Paper
Ask AI
Bookmark
Share

Authors

LFLaura FogliattoFCFilipa CordeiroACAugustin Penedo Coello

Discussion

Loading...

Member takes

Overview

Single-arm study shows 89% overall response rate with BI-1206, rituximab, and acalabrutinib in R/R NHL, highlighting safety and efficacy.

Key Points

  • Overall response rate reached 89%, indicating substantial efficacy in R/R NHL treatment.
  • Combination approach yielded manageable adverse events, with 87% classified as mild or moderate.
  • Single-arm analysis involving BI-1206, rituximab, and acalabrutinib was conducted with 30 enrolled R/R NHL patients.
  • Continued investigation into the safety and efficacy of this novel combination therapy is warranted.

Cite This Study

Fogliatto et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db51https://doi.org/10.1182/blood-2025-5349
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Zanubrutinib combined with bendamustine and rituximab in previously untreated patients with advanced follicular lymphoma: A prospective, open-label, single-arm phase II clinical study2025
  2. 2Preliminary study results of orelabrutinib in combination with rituximab for treatment-Naïve marginal zone lymphoma: A prospective single-arm clinical trial2025 · 1 citations
  3. 3Efficacy and safety of zanubrutinib combined with anti-CD20 monoclonal antibody-based regimens as first-line therapy in high-risk follicular lymphoma and marginal zone lymphoma: A single-arm retrospective study2025
  4. 4Efficacy and safety of zanubrutinib combined with chemotherapy in the treatment of relapsed/refractory diffuse large B-cell lymphoma2025
  5. 5Ibrutinib plus R-CHOP followed by maintenance in untreated ABC-DLBCL patients with IPI ≥2: A first analysis of phase II Study  FIL_RI-CHOP2025